In this SDPA Conference interview, Zirwas continues his discussion of increasing environmental impacts on rates of atopic dermatitis.
Building on his prior interview discussion regarding environmental drivers of atopic dermatitis, Matthew Zirwas, MD, touched on emerging research exploring the role of toluene diisocyanate (TDI), an industrial chemical he believes may help explain the increasing rates of eczema observed over the past several decades.1
Speaking with HCPLive following his presentation at the
He noted that the proposed association is supported not only by epidemiologic findings but also by mechanistic evidence. Zirwas described TDI as being already recognized by the US Food and Drug Administration (FDA) to be a substance capable of inducing eczema in animal models. He also noted its common use in preclinical research to determine atopic dermatitis before evaluating investigational drugs. He pointed to this biological evidence, combined with the geographic correlations, as making TDI a compelling area for continued investigation.
According to Zirwas, timing and distribution of TDI exposure also align with longstanding epidemiologic observations, including the noted increase in atopic dermatitis beginning in the 1970s and the higher prevalence of disease in urban environments.1,2 While he acknowledged that research in this area is ongoing, he described the hypothesis as one that brings together several previously unexplained patterns in atopic dermatitis.
Additionally, Zirwas also discussed how this information could eventually impact patient counseling, suggesting practical strategies designed to reduce exposure. Such strategies included choosing older upholstered furniture in which polyurethane foam has already off-gassed much of its TDI, limiting exposure to polyester and nylon clothing when possible, and recognizing the potential contribution of urban environmental exposures to disease risk.
For the purposes of communicating these concepts to families, Zirwas pointed a recently released children's book implementing Winnie-the-Pooh characters to explain environmental factors connected with developing eczema and strategies that may help diminish patients’ levels of risk.
Disclosures: Galderma Laboratories, L.P, Regeneron Healthcare Solutions, GENZYME CORPORATION, Arcutis Biotherapeutics, Lilly USA, Novartis Pharmaceuticals Corporation, Dermavant Sciences, LEO Pharma, Verrica Pharmaceuticals, Incyte Corporation, AbbVie, and Pfizer.
References
